Financial Performance - The company's operating revenue for Q1 2024 was ¥5,196,134,001.26, representing a 3.50% increase compared to ¥5,020,539,960.94 in the same period last year[2]. - Net profit attributable to shareholders for Q1 2024 was ¥899,476,291.54, reflecting a 15.16% increase from ¥781,064,898.92 year-on-year[2]. - Basic earnings per share increased by 15.50% to ¥0.0976 from ¥0.0845 in the same period last year[2]. - The total profit for Q1 2024 was CNY 1,202,607,404.60, an increase from CNY 1,132,980,006.15 in Q1 2023, representing a growth of approximately 6.1%[18]. - The total operating costs for Q1 2024 were CNY 4,021,509,579.51, compared to CNY 3,896,380,425.67 in Q1 2023, reflecting an increase of about 3.2%[17]. Cash Flow - The net cash flow from operating activities decreased by 21.91% to ¥1,290,939,304.47 from ¥1,653,223,002.26 in the previous year[2]. - The cash inflow from operating activities amounted to ¥5,256,300,803.12, an increase of 9.45% compared to ¥4,802,636,185.86 in the previous period[20]. - The cash outflow for investing activities totaled ¥455,322,713.03, significantly lower than ¥1,192,694,050.05 in the previous period, indicating a reduction of 61.86%[21]. - The net cash flow from investing activities was -¥440,953,103.74, an improvement from -¥879,272,407.99 in the previous period[21]. - The cash inflow from financing activities was ¥20,082,246.74, slightly down from ¥21,696,824.07 in the previous period[21]. - The net cash flow from financing activities decreased to -¥305,067,125.92, compared to -¥215,262,680.44 in the previous period[21]. Assets and Liabilities - Total assets at the end of Q1 2024 were ¥30,899,280,579.23, up 2.36% from ¥30,186,619,945.52 at the end of the previous year[2]. - The total liabilities decreased to CNY 9,975,555,946.18 from CNY 10,161,858,405.60, a reduction of approximately 1.8%[16]. - The total equity increased to CNY 20,923,724,633.05 from CNY 20,024,761,539.92, marking an increase of about 4.5%[16]. - The company's retained earnings rose to CNY 9,279,591,326.10 from CNY 8,380,115,034.56, an increase of approximately 10.7%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 338,428[7]. - The largest shareholder, Aier Medical Investment Group, holds 3,202,323,587 shares, representing 34.33% of total shares[7]. - The second-largest shareholder, Chen Bang, holds 15.48% of the shares, amounting to 1,443,791,891 shares[7]. - The company has a diverse shareholder base, including domestic and foreign entities, with varying percentages of ownership[7]. - The top ten shareholders collectively hold a significant portion of the company's shares, with no shareholder among them having a relationship that would classify them as acting in concert[8]. Research and Development - The company reported a 12.18% increase in R&D expenses, totaling ¥74,654,886.82 compared to ¥66,549,935.52 in the previous year[6]. - Research and development expenses for Q1 2024 were CNY 74,654,886.82, up from CNY 66,549,935.52 in Q1 2023, indicating an increase of approximately 12.5%[17]. Other Income and Expenses - Other income surged by 660.70% to ¥85,081,860.24 from ¥11,184,692.01, primarily due to increased government subsidies received by subsidiaries[6]. - The company experienced a 46.37% decline in investment income, which fell to ¥1,823,265.17 from ¥3,399,520.17 year-on-year[6]. - Other comprehensive income after tax for Q1 2024 was CNY -34,939,834.55, compared to CNY 14,330,809.88 in Q1 2023, indicating a significant decline[18]. Inventory and Assets Management - The company reported a decrease in inventory from 899,686,324.79 yuan to 776,094,375.87 yuan, a decline of about 13.7%[13]. - Cash and cash equivalents increased to 6,625,981,574.50 yuan from 6,099,082,253.65 yuan, representing an increase of approximately 8.6%[13]. - Accounts receivable rose to 2,105,478,461.95 yuan from 1,899,196,193.66 yuan, reflecting an increase of about 10.9%[13]. - Total current assets increased to 10,812,490,202.36 yuan from 10,185,995,877.77 yuan, marking a growth of approximately 6.1%[14]. - Non-current assets totaled 20,086,790,376.87 yuan, slightly up from 20,000,624,067.75 yuan, indicating a marginal increase[14].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 10 billion RMB, representing a year-over-year growth of 15%[6]. - The company reported a net profit margin of 18%, reflecting improved operational efficiency[9]. - The company reported a net profit attributable to shareholders for 2023 was approximately ¥3.36 billion, up 33.07% from ¥2.52 billion in 2022[18]. - The total operating revenue for 2023 reached approximately ¥20.37 billion, representing a 26.43% increase compared to ¥16.11 billion in 2022[18]. - The company reported a significant increase in cash flow from operating activities, with Q3 2023 generating approximately ¥2.21 billion[19]. - The company reported a non-recurring loss of ¥154,902,483.57 in 2023, compared to a loss of ¥394,544,981.09 in 2022, indicating a significant reduction in non-recurring losses year-over-year[21]. - The company reported a quarterly revenue of approximately ¥5.80 billion in Q3 2023, with a net profit of approximately ¥1.47 billion for the same period[19]. - The company reported a significant increase in the number of myopia prevention cases due to the promotion of its 5P myopia prevention system[58]. Strategic Initiatives - The company plans to expand its market presence by opening 10 new hospitals in tier-2 cities within the next 18 months[6]. - The company is investing 200 million RMB in research and development for innovative eye care solutions over the next two years[6]. - The company is expanding its market presence by opening 10 new hospitals across various provinces in China in 2024[8]. - The company is actively involved in initiatives to enhance eye health services, aligning with national health planning and policies aimed at improving public health outcomes[26]. - The company is committed to expanding its services in response to the increasing demand for specialized medical care, driven by government policies and public health initiatives[23]. - The company is focused on expanding its market presence through strategic acquisitions and investments in the healthcare sector[166]. Research and Development - The company established 17 research institutes to enhance its clinical and research capabilities[32]. - The company is investing in R&D for innovative eye care technologies, with research on innovative drugs for dry age-related macular degeneration (AMD) ongoing[68]. - The company is developing an AI-assisted calculation formula for intraocular lenses tailored for high myopia cataract patients, aiming for higher accuracy and targeted application[68]. - The company has developed multiple AI-based ophthalmic imaging analysis algorithms and intelligent diagnostic systems, improving examination efficiency by over 30%[40]. - The company is focusing on myopia prevention and control in children and adolescents, with plans to publish multiple papers and apply for several patents[68]. Operational Efficiency - Operational efficiency initiatives have led to a 10% reduction in costs, contributing to improved profit margins[7]. - The company has implemented a comprehensive medical quality management system, achieving full coverage of safety quality indicators through high-frequency inspections and digital monitoring[34]. - The company’s digital transformation in medical quality management improved regulatory efficiency and safety monitoring[34]. - The company has implemented a digital management system to enhance operational efficiency and financial risk control[49]. - The company has established an internal control system that meets regulatory requirements and effectively manages related risks[172]. Market Trends and Growth - The aging population in China is projected to exceed 400 million by 2050, driving demand for age-related eye disease treatments[28]. - The overall myopia rate among children and adolescents in China reached 51.9% in 2022, indicating a growing market for eye health services[28]. - The company’s market share continues to grow, supported by increasing brand influence and the implementation of national eye health policies[56]. - The company is exploring potential mergers and acquisitions to enhance its service capabilities and market share, with a focus on strategic partnerships[156]. Governance and Compliance - The company emphasized the importance of accurate and complete financial reporting, with all board members present for the approval of the annual report[2]. - The company has not reported any discrepancies between net profit and net assets under international accounting standards and Chinese accounting standards during the reporting period[20]. - The company maintains independence from its controlling shareholder in terms of personnel, assets, finance, and operations[149]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[147]. - The company strictly adheres to legal regulations for information disclosure, ensuring timely and accurate communication with investors[148]. Employee Engagement and Development - The company has implemented a multi-faceted incentive mechanism combining salary, bonuses, stock options, and restricted stock to align employee compensation with company performance[179]. - The company has a total of 6,519 health education personnel and 2,362 financial personnel among its workforce[178]. - The company’s employee training plan includes both internal and external training to enhance staff capabilities and meet development needs[180]. - The company aims to improve employee engagement and retention through a robust talent management system and various incentive programs[135]. Customer Satisfaction and Service Quality - The overall patient satisfaction rate has improved to 95%, reflecting the company's commitment to quality service[7]. - The company achieved a 100% coverage rate for patient satisfaction survey management systems, continuously optimizing tools to improve patient satisfaction[36]. - The company emphasizes a patient-centered service model, optimizing processes to enhance the overall patient experience during medical visits[35]. - The company’s quality control standards include guidelines for refractive cataract surgery and outpatient management, ensuring compliance with national health regulations[34].

关于计提资产减值准备及核销资产的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 证券代码：300015 股票简称：爱尔眼科 公告编号：2024-028 爱尔眼科医院集团股份有限公司 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2024年4月25日召开 第六届董事会第二十次会议，第六届监事会第十二次会议，审议通过了《关于计提 资产减值准备及核销资产的议案》，本次核销资产不涉及关联方，在董事会权限范 围内，无需提交股东大会审议。具体内容公告如下： | 项目 | 期初余额 | 本期计提 | 合并转入 | 转回 | 核（转） | 外币折算 | 期末余额 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | （+） | 销（-） | 差异 | | 一、本次计提资产减值准备及核销资产情况的概述 为真实反映公司的财务状况、资产价值及经营情况，根据《企业会计准则》、 《深圳证券交易所创业板上市公司规范运作指引》等相关规定，以及公司会计政策 和会计估计，本着谨慎性原则，对公司及下属子公司截至2023年 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2024-027 爱尔眼科医院集团股份有限公司 二、拟续聘会计师事务所的基本情况 关于聘请 2024 年年度审计机构的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于2024年4月25日召 开第六届董事会第二十次会议，审议通过了《关于聘请2024年年度审计机构的 议案》，同意续聘中审众环会计师事务所（特殊普通合伙)（以下简称"中审众 环"）为公司2024年年度审计机构，并提请股东大会授权公司经营管理层根据 实际审计业务范围和市场价格水平确定相关审计费用，提交公司2023年年度股 东大会审议。现将有关事项公告如下： 一、拟聘任会计师事务所事项的情况说明 本次拟续聘中审众环会计师事务所（特殊普通合伙）为公司 2024 年年度审 计机构。 公司第六届董事会审计委员会已听取中审众环会计师事务所关于公司 2023 年年审工作的总结,审阅了该会计师事务所出具的公司 2023 年年度财务报告审 计报告众环审字（2024）0101327 号和内部控制鉴证报告众环专字（202 ...

2023 年度社会责任报告 爱尔眼科医院集团股份有限公司 AIER EYE HOSPITAL GROUP CO., LTD. 2023 年度社会责任报告 关于本报告 报告简介 《爱尔眼科医院集团股份有限公司 2023 年度社会责任报告》（亦称之为《爱尔眼科医院集团股份有限公司 2023 年度可持续发展报告》，以下简称"本报告"）是爱尔眼科医院集团股份有限公司对外发布的第十五份 社会责任报告。本报告遵循客观、规范、透明和全面的原则，真实、详细反映了公司 2023 年在环境、社会及 管治（以下简称"ESG"）等社会责任领域的管理策略、实践与绩效，旨在与各利益相关方进行有效交流，系 统地回应利益相关方的期望和要求。 时间范围 2023 年 1 月 1 日至 2023 年 12 月 31 日。为增强报告可比性，部分内容超出此范围。 发布周期 本报告为年度报告，上期报告于 2023 年 4 月发布。 报告范围 本报告组织范围为爱尔眼科医院集团股份有限公司、爱尔眼科在中华人民共和国的运营子公司及爱尔眼科在中 国香港、美国、欧洲、东南亚的分支机构（以下简称"爱尔眼科""集团" "公司"或"我们"）。 编制依据 全球可持续发 ...

根据《证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所创 业板上市公司自律监管指南第1号——业务办理》和《深圳证券交易所上市公司 自律监管指引第2号——创业板上市公司规范运作》等有关规定的要求，爱尔眼 科医院集团股份有限公司（以下简称"公司"）董事会对2023年年度证券与衍生 品投资情况进行了核查，现将相关情况说明如下： 爱尔眼科医院集团股份有限公司 2023年年度证券与衍生品投资情况的专项报告 一、证券投资概述 公司在投资风险可控且不影响正常经营的情况下，使用自有资金开展证券投 资，以充分提高资金收益和使用效率。2023 年度，公司未新增证券投资与衍生 品投资，相关公允价值变动的具体情况详见附表。 二、证券与衍生品投资的审议情况 公司于 2022 年 1 月 5 日召开第五届董事会第四十七次会议及第五届监事会 第二十三次会议，审议通过了《关于开展金融衍生品交易业务的议案》，同意公 司及其子公司新开展名义本金不超过人民币 10 亿元的金融衍生品交易业务。鉴 于外汇市场波动性增加，为降低汇率及利率波动对公司经营业绩的影响，公司及 其子公司拟结合实际业务需要，开展以套期保值为目的的金融衍生品交易业务， ...

二、形成审计意见的基础 审 计 报 告 众环审字(2024)0101327 号 爱尔眼科医院集团股份有限公司全体股东： 一、审计意见 我们审计了爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"）财务报表，包括 2023 年 12 月 31 日的合并及公司资产负债表，2023 年度的合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 爱尔眼科 2023 年 12 月 31 日合并及公司的财务状况以及 2023 年度合并及公司的经营成果和 现金流量。 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则，我们独立于爱尔眼科，并履行了职业道德方面的其他责任。我们相信，我们获 取的审计证据是充分、适当的，为发表审计意见提供了基础。 三、关键审计事项 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事项。这些事 项的应对以对财务报表整体进行审计并形成审计意见为背景，我们不 ...

证券代码：300015 证券简称：爱尔眼科 公告编号：2024-022 爱尔眼科医院集团股份有限公司 一、《2023 年年度监事会工作报告》； 具体内容详见巨潮资讯网（ www.cninfo.com.cn ）披露的《2023 年年度监 事会工作报告》。 该议案以 3 票同意，0 票反对，0 票弃权获得通过。 此议案尚需提交股东大会审议。 二、《2023 年年度报告》及《2023 年年度报告摘要》； 监事会认为：董事会编制和审核公司2023年年度报告的程序符合法律、行政 法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司2023年度经 营的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。具体内容详见 巨潮资讯网（ www.cninfo.com.cn ）披露的《2023年年度报告》及《2023年年 度报告摘要》。 第六届监事会第十二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届监事会第十二 次会议于 2024 年 4 月 25 日在长沙市天心区芙蓉南路一段 188 号爱尔大厦会议室 ...

独立董事2023 年年度述职报告 爱尔眼科医院集团股份有限公司 独立董事 2023 年年度述职报告 郭月梅 本人作为爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"或"公司"） 的独立董事，在任职期间严格按照《公司法》《证券法》《上市公司独立董事规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《公司章程》《独立董事工作制度》等相关法律、法规、规章的规定和要 求，在2023年工作中，诚实、勤勉、独立的履行职责，积极出席相关会议，认真 审议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事及 各专门委员会的作用。现向董事会和股东大会提交2023年年度述职报告，对履行 职责的情况进行说明，请予审查。 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人郭月梅，澳大利亚莫纳什大学税法博士，中南财经政法大学财政税务学 院二级教授，博士生导师，高级会计师，澳大利亚注册会计师。2019 年 12 月起 任爱尔眼科独立董事。兼任精伦电子、楚天智能、力源信息独立董事。 （二）不存在影响独立性的情况 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在 ...

爱尔眼科医院集团股份有限公司 关于会计师事务所 2023 年度履职情况的评估报告 爱尔眼科医院集团股份有限公司（以下简称"公司"）聘请中审众环会计师 事务所（特殊普通合伙）（以下简称"中审众环"）作为公司 2023 年度年报审 计机构，根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师 事务所管理办法》，公司董事会审计委员会对中审众环 2023 年审计过程中的履 职情况进行评估，具体情况如下: 一、资质条件 （1）机构名称：中审众环会计师事务所（特殊普通合伙） （2）成立日期：中审众环始创于 1987 年，是全国首批取得国家批准具有从 事证券、期货相关业务资格及金融业务审计资格的大型会计师事务所之一。根据 财政部、证监会发布的从事证券服务业务会计师事务所备案名单，本所具备股份 有限公司发行股份、债券审计机构的资格。2013 年 11 月，按照国家财政部等有 关要求转制为特殊普通合伙制。 （3）2023 年末合伙人数量 216 人、注册会计师数量 1,244 人、签署过证券 服务业务审计报告的注册会计师人数 716 人。 （4）2023 年度上市公司审计客户家数 201 家，主要行业涉及制造业，批发 ...